Artelo Strengthens Leadership With Appointment Of Mark Spring, CPA, As Chief Financial Officer

Artelo Biosciences, Inc., a clinical-stage pharmaceutical company developing therapies that modulate lipid-signalling pathways for cancer, pain, dermatological, and neurological conditions, has announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025. Mr. Spring has been serving as a financial consultant to Artelo since December 2024. His appointment strengthens the company’s financial and strategic leadership as it advances its clinical pipeline and corporate growth plans.

“Mark’s extensive experience across commercial-stage and development-stage biopharmaceutical companies makes him an outstanding addition to our leadership team,” said Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences. “Since his engagement in December, Mark has strengthened our financial operations, supported the execution of our capital strategy, and enhanced our shareholder communications. His experience and steady leadership are expected to be instrumental as we advance our product candidates and build shareholder value.”

With over three decades of experience in the life sciences industry, Mr. Spring brings a strong background in leading financial operations for private and public, multinational, and development-stage companies. Most recently, he served as interim CFO at LENZ Therapeutics during its reverse merger and was co-founder and CFO of Secura Bio, a commercial-stage oncology firm. His prior roles include CFO positions at Hyperion Therapeutics, Prometheus Laboratories, Veracyte, Sotera Wireless, and Genoptix.

“I have developed strong conviction in Artelo’s strategy, development programs and leadership,” said Mark Spring. “Working closely with the team has given me a clear view of the Company’s operational strengths, prudent approach to capital allocation, and commitment to advancing high-value programs. I’m confident in Artelo’s potential and look forward to helping drive disciplined financial execution and long-term growth.”

Mr. Spring also brings extensive M&A and licensing experience, having played key roles in significant transactions at Caremark, Dade Behring, Baxter, MedImmune, Prometheus, and Genoptix. He earned his BA in Business Administration from Monmouth College, pursued postgraduate studies at the University of Texas at Dallas, and is an active Certified Public Accountant (CPA).